ArticleFrontiers in chemistry2025
Formal synthesis of dibenzotetrathiafulvalene (DBTTF), through practical electrochemical preparation of benzo[d]-1,3-dithiole-2-one (BDTO).
Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study focuses on developing an electrochemical reaction to produce benzo[d]-1,3-dithiole-2-one (BDTO). This compound serves as a direct precursor for dibenzotetrathiafulvalenes (DBTTF), an important member of the charge transfer complex family. BDTO is synthesized in three steps (16%) starting from aniline. The key reaction is an anodically driven intramolecular cyclization (35%), involving a thiyl radical-cation intermediate formed from the oxidation of the S-aryl-O-ethyldithiocarbonate derivative. This derivative is obtained in good yields from its respective aromatic diazonium salt. This approach eliminates the need for advanced, costly intermediates and avoids long, complex synthetic routes previously used to produce BDTO, utilizing safer and cheaper reagents. This opens the door to generating DBTTF derivatives quickly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.